BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 17335207)

  • 1. Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system.
    Bowman AL; Lerner MG; Carlson HA
    J Am Chem Soc; 2007 Mar; 129(12):3634-40. PubMed ID: 17335207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specificity in structure-based drug design: identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase.
    Gschwend DA; Sirawaraporn W; Santi DV; Kuntz ID
    Proteins; 1997 Sep; 29(1):59-67. PubMed ID: 9294866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate.
    Senkovich O; Schormann N; Chattopadhyay D
    Acta Crystallogr D Biol Crystallogr; 2009 Jul; 65(Pt 7):704-16. PubMed ID: 19564691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating dynamics in E. coli dihydrofolate reductase enhances structure-based drug discovery.
    Lerner MG; Bowman AL; Carlson HA
    J Chem Inf Model; 2007; 47(6):2358-65. PubMed ID: 17877338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards in silico lead optimization: scores from ensembles of protein/ligand conformations reliably correlate with biological activity.
    Popov VM; Yee WA; Anderson AC
    Proteins; 2007 Feb; 66(2):375-87. PubMed ID: 17078091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(omega-carboxy(alkyloxy) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions.
    Cody V; Pace J; Chisum K; Rosowsky A
    Proteins; 2006 Dec; 65(4):959-69. PubMed ID: 17019704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FlexE: efficient molecular docking considering protein structure variations.
    Claussen H; Buning C; Rarey M; Lengauer T
    J Mol Biol; 2001 Apr; 308(2):377-95. PubMed ID: 11327774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
    Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
    Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
    Graffner-Nordberg M; Kolmodin K; Aqvist J; Queener SF; Hallberg A
    Eur J Pharm Sci; 2004 May; 22(1):43-54. PubMed ID: 15113582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
    Gangjee A; Guo X; Queener SF; Cody V; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Apr; 41(8):1263-71. PubMed ID: 9548816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 2.13 A structure of E. coli dihydrofolate reductase bound to a novel competitive inhibitor reveals a new binding surface involving the M20 loop region.
    Summerfield RL; Daigle DM; Mayer S; Mallik D; Hughes DW; Jackson SG; Sulek M; Organ MG; Brown ED; Junop MS
    J Med Chem; 2006 Nov; 49(24):6977-86. PubMed ID: 17125251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and comparative studies of zebrafish and human recombinant dihydrofolate reductases--inhibition by folic acid and polyphenols.
    Kao TT; Wang KC; Chang WN; Lin CY; Chen BH; Wu HL; Shi GY; Tsai JN; Fu TF
    Drug Metab Dispos; 2008 Mar; 36(3):508-16. PubMed ID: 18056255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the optimal third generation antifolate against P. falciparum and P. vivax.
    Hunt SY; Detering C; Varani G; Jacobus DP; Schiehser GA; Shieh HM; Nevchas I; Terpinski J; Sibley CH
    Mol Biochem Parasitol; 2005 Dec; 144(2):198-205. PubMed ID: 16181688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure determination of tetrahydroquinazoline antifolates in complex with human and Pneumocystis carinii dihydrofolate reductase: correlations between enzyme selectivity and stereochemistry.
    Cody V; Luft JR; Pangborn W; Gangjee A; Queener SF
    Acta Crystallogr D Biol Crystallogr; 2004 Apr; 60(Pt 4):646-55. PubMed ID: 15039552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.
    Fogel GB; Cheung M; Pittman E; Hecht D
    J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
    Kuyper LF; Baccanari DP; Jones ML; Hunter RN; Tansik RL; Joyner SS; Boytos CM; Rudolph SK; Knick V; Wilson HR; Caddell JM; Friedman HS; Comley JC; Stables JN
    J Med Chem; 1996 Feb; 39(4):892-903. PubMed ID: 8632413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of human dihydrofolate reductase activity and expression.
    Abali EE; Skacel NE; Celikkaya H; Hsieh YC
    Vitam Horm; 2008; 79():267-92. PubMed ID: 18804698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening.
    Wyss PC; Gerber P; Hartman PG; Hubschwerlen C; Locher H; Marty HP; Stahl M
    J Med Chem; 2003 Jun; 46(12):2304-12. PubMed ID: 12773035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stoichiometric selection of tight-binding inhibitors by wild-type and mutant forms of malarial (Plasmodium falciparum) dihydrofolate reductase.
    Kamchonwongpaisan S; Vanichtanankul J; Tarnchompoo B; Yuvaniyama J; Taweechai S; Yuthavong Y
    Anal Chem; 2005 Mar; 77(5):1222-7. PubMed ID: 15732900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of the inhibition of bovine liver dihydrofolate reductase by tea catechins: origin of slow-binding inhibition and pH studies.
    Navarro-Perán E; Cabezas-Herrera J; Hiner AN; Sadunishvili T; García-Cánovas F; Rodríguez-López JN
    Biochemistry; 2005 May; 44(20):7512-25. PubMed ID: 15895994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.